Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor

• Published in: Therapeutic advances in medical oncology Vol. 15; p. 17588359231200463
• Main Authors: He, Li-Na, Chen, Tao, Fu, Sha, Jiang, Yongluo, Zhang, Xuanye, Chen, Chen, Du, Wei, Luo, Linfeng, Li, Anlin, Wang, Yixing, Yu, Hui, Zhou, Yixin, Wang, Yuhong, Yang, Yunpeng, Huang, Yan, Zhao, Hongyun, Fang, Wenfeng, Zhang, Li, Hong, Shaodong
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2023; Sage Publications Ltd; SAGE Publishing
• Subjects: Antitumor activity; Lesions; Lung cancer; Multivariate analysis; Non-small cell lung carcinoma; Original Research; PD-1 protein; PD-L1 protein; Small cell lung carcinoma; Solid tumors; Statistical analysis; non-small cell lung cancer; RECIST 1.1; tumor response; immunotherapy; modified RECIST 1.1; target lesion
• ISSN: 1758-8359; 1758-8340; 1758-8359
• DOI: 10.1177/17588359231200463

Background: For Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1), measuring up to two target lesions per organ is an arbitrary criterion. Objectives: We sought to compare response assessment using RECIST1.1 and modified RECIST1.1 (mRECIST1.1, measuring the single largest lesion per organ) in advanced non-small cell lung cancer (aNSCLC) patients undergoing anti-PD-1/PD-L1 monotherapy. Methods: Concordance of radiologic response categorization between RECIST1.1 and mRECIST1.1 was compared using the Kappa statistics. C-index was calculated to evaluate prognostic accuracy of radiologic response by the two criteria. The Kaplan–Meier method and Cox regression analysis were conducted for progression-free survival (PFS) and overall survival (OS). Results: Eighty-seven patients who had at least two target lesions in any organ per the RECIST1.1 were eligible for comparison analysis. Tumor response showed excellent concordance when measured using the RECIST1.1 and mRECIST1.1 (Kappa = 0.961). C-index by these two criteria was similar for PFS (0.784 versus 0.785) and OS (0.649 versus 0.652). Responders had significantly longer PFS and OS versus non-responders (p < 0.05), whichever criterion adopted. Radiologic response remained a significant predictor of PFS and OS in multivariate analysis (p < 0.05). Conclusion: The mRECIST1.1 was comparable to RECIST1.1 in response assessment among aNSCLC patients who received single-agent PD-1/PD-L1 inhibitor. The mRECIST1.1, with reduced number of lesions to be measured, may be sufficient and more convenient to assess antitumor activity in clinical practice.